In summary, this study is the first to support the hypothesis that JAK2-mutated patients exhibit increased cancer immunogenicity and anticancer immunity, leading to an enhanced response to and long-term survival benefits of ICI therapy. This evidence concerns the gene JAK2 and cancer.